On the 26th April 2016, PNAS published the article: “Human DDX3 Protein: a New Valuable Target to Develop Broad Spectrum Antiviral Agents” describing part of the antiviral research performed by collaborating groups in Italy and Spain.
The subject of this publication is of significant importance because it describes and presents proof of the completely novel and highly effective cell biological working mechanism of our RNA Helicase inhibiting antiviral technology. The article addresses the efficacy of our compounds against several viral pathogens such as HIV, Hepatitis C, West Nile and Dengue virus, with specific interest for multiple Anti Retroviral Therapy resistant HIV strains, as well as the absence of toxicity verified in both in-vitro and in-vivo assays.
PNAS – Proceedings of the National Academy of Sciences of the United States of America, is one of the most renowned and most high cited peer reviewed scientific journals in the world, and we made arrangements so that the article is freely available to all readers in open access. You will find it here on the website of PNAS.
- On April 26, 2016